| review article | Q7318358 |
| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P50 | author | Kazuhiro Ito | Q87778476 |
| Ian M. Adcock | Q38803002 | ||
| Kian Fan Chung | Q43222898 | ||
| P2093 | author name string | Gaetano Caramori | |
| P2860 | cites work | The protein kinase complement of the human genome | Q24324497 |
| Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells | Q24672520 | ||
| Pharmacotherapy and airway remodelling in asthma? | Q24678822 | ||
| Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells | Q24791093 | ||
| Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site | Q27638349 | ||
| Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase | Q27640156 | ||
| Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity | Q27641774 | ||
| The role of PI3K in immune cells | Q28186713 | ||
| Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID | Q28241595 | ||
| c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis | Q28343409 | ||
| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Q28364720 | ||
| MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis | Q28593865 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| Missing pieces in the NF-kappaB puzzle | Q29547864 | ||
| Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation | Q29614227 | ||
| Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases | Q29614338 | ||
| Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. | Q45207907 | ||
| Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium | Q46522256 | ||
| Mitogen-activated protein kinase cascades as regulators of stress responses | Q46899777 | ||
| SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung | Q46903300 | ||
| Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. | Q51702183 | ||
| Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. | Q51721285 | ||
| The global burden of disease, 1990–2020 | Q53681952 | ||
| In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. | Q54079350 | ||
| Expression and activation of protein kinase C-zeta in eosinophils after allergen challenge. | Q54458959 | ||
| Fos immunoreactivity assessment on human normal and pathological bronchial biopsies. | Q54567044 | ||
| Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. | Q54692531 | ||
| Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. | Q55034563 | ||
| Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab | Q57244635 | ||
| A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma | Q57956064 | ||
| Defective T Cell Differentiation in the Absence of Jnk1 | Q58415329 | ||
| Cellular protein kinase C activity in asthma | Q73227864 | ||
| IKKβ Is Required for Peripheral B Cell Survival and Proliferation | Q73299772 | ||
| Vascular endothelial growth factor and the pathogenesis of emphysema | Q73315628 | ||
| Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway | Q80985173 | ||
| An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment | Q81606189 | ||
| Chronic obstructive pulmonary disease | Q93936786 | ||
| Cellular functions regulated by Src family kinases | Q29616038 | ||
| The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 | ||
| Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain | Q29620169 | ||
| Direct interaction of Syk and Lyn protein tyrosine kinases in rat basophilic leukemia cells activated via type I Fc epsilon receptors. | Q30176694 | ||
| The potential role of PKC beta in diabetic retinopathy and macular edema | Q31123344 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus | Q33539989 | ||
| Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease | Q33956768 | ||
| Inhibition of p38 MAP kinase as a therapeutic strategy | Q33957191 | ||
| Protein kinase C isozymes and the regulation of diverse cell responses | Q34012841 | ||
| Asthma. | Q34137112 | ||
| Update on glucocorticoid action and resistance | Q34171161 | ||
| Cellular and structural bases of chronic obstructive pulmonary disease | Q34260279 | ||
| Signalling from the cell surface to the nucleus | Q34471547 | ||
| Protein kinase C inhibitors as novel anticancer drugs | Q34481881 | ||
| p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. | Q34483284 | ||
| NF-kappa B as a therapeutic target in multiple myeloma | Q34521393 | ||
| JAK-STAT signaling in asthma | Q34647024 | ||
| Emerging immune targets for the therapy of allergic asthma | Q34741560 | ||
| NF-kappaB as a therapeutic target in cancer | Q34750172 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors | Q34750411 | ||
| New concepts in chronic obstructive pulmonary disease | Q34930970 | ||
| Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat. | Q35042718 | ||
| A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. | Q35043860 | ||
| Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase | Q35045982 | ||
| CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities | Q35048762 | ||
| A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity | Q35048852 | ||
| Epidermal growth factor system regulates mucin production in airways | Q35065617 | ||
| Tyrosine kinases as targets in cancer therapy - successes and failures | Q35095147 | ||
| Targeting the JNK pathway for therapeutic benefit in CNS disease | Q35137435 | ||
| Targeting JNK for therapeutic benefit: from junk to gold? | Q35158010 | ||
| Targeting epidermal growth factor receptor--are we missing the mark? | Q35174501 | ||
| Pharmacology of airway inflammation in asthma and COPD. | Q35183830 | ||
| p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases | Q35209995 | ||
| Corticosteroid-insensitive asthma: molecular mechanisms. | Q35216182 | ||
| Tyrosine kinase inhibitors: a new approach for asthma | Q35692069 | ||
| Protein kinase inhibitors: insights into drug design from structure. | Q35697409 | ||
| PI 3-kinase inhibition: a therapeutic target for respiratory disease | Q35717638 | ||
| The p38 MAP kinase pathway as a therapeutic target in inflammatory disease | Q35834912 | ||
| Lung inflammation as a therapeutic target in cystic fibrosis. | Q35894285 | ||
| The role of sphingosine and ceramide kinases in inflammatory responses | Q35976753 | ||
| The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation | Q36107319 | ||
| Respiratory syncytial virus pneumonia: mechanisms of inflammation and prolonged airway hyperresponsiveness | Q36111797 | ||
| Strategies for the design of potent and selective kinase inhibitors. | Q36126762 | ||
| Activation and localization of transcription factor, nuclear factor-kappaB, in asthma | Q38331366 | ||
| Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia | Q38919861 | ||
| BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. | Q40448987 | ||
| Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells | Q40553683 | ||
| Regulation of airway epithelial cell NF-kappa B-dependent gene expression by protein kinase C delta | Q40646086 | ||
| A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance | Q40691411 | ||
| Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate | Q40721991 | ||
| Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase | Q40857729 | ||
| Involvement of the epidermal growth factor receptor in epithelial repair in asthma | Q40870399 | ||
| p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells | Q40895310 | ||
| Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis | Q40929895 | ||
| The costs of asthma | Q41050636 | ||
| The epithelium as a target of glucocorticoid action in the treatment of asthma | Q41075168 | ||
| Developmental expression in the mouse nervous system of the p493F12 SAP kinase | Q41251934 | ||
| Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells | Q41700451 | ||
| Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury | Q41982755 | ||
| Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. | Q42537136 | ||
| Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils | Q42943439 | ||
| p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma | Q43952642 | ||
| Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight | Q44011810 | ||
| Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase | Q44050002 | ||
| BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice | Q44196757 | ||
| Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome | Q44321379 | ||
| Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice | Q44410698 | ||
| The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents | Q44453360 | ||
| A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts | Q44482174 | ||
| Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. | Q44558810 | ||
| Distribution of therapeutic response in asthma control | Q44600710 | ||
| AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells | Q44645811 | ||
| Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokin | Q45021806 | ||
| Treatment of cockroach allergen asthma model with imatinib attenuates airway responses | Q45063930 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 118-132 | |
| P577 | publication date | 2006-02-08 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Kinase inhibitors and airway inflammation | |
| P478 | volume | 533 |
| Q41287485 | A high-throughput chemical screen identifies novel inhibitors and enhancers of anti-inflammatory functions of the glucocorticoid receptor |
| Q50627197 | Activation of MAPK participates in low shear stress-induced IL-8 gene expression in endothelial cells. |
| Q41869210 | Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV1 in COPD patients |
| Q46213809 | Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease |
| Q36724014 | Airway smooth muscle cell as therapeutic target of inflammation |
| Q35600403 | Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma |
| Q37184811 | Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids |
| Q54620014 | Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship. |
| Q104993532 | Anti-inflammatory Activity |
| Q33774669 | Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke. |
| Q82041601 | Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation |
| Q34131740 | Atg7 deficiency impairs host defense against Klebsiella pneumoniae by impacting bacterial clearance, survival and inflammatory responses in mice |
| Q61712331 | Attenuation of Ozone-Induced Airway Inflammation and Hyper-Responsiveness by c-Jun NH2 Terminal Kinase Inhibitor SP600125 |
| Q37596127 | Basal p38 mitogen-activated protein kinase regulates unliganded glucocorticoid receptor function in airway smooth muscle cells. |
| Q37411345 | Bronchial asthma, chronic obstructive pulmonary disease and NF-kappaB. |
| Q37856648 | Chronic obstructive pulmonary disease and lung cancer: new molecular insights |
| Q36443665 | Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities |
| Q39602460 | Cigarette smoke extract regulates cytosolic phospholipase A2 expression via NADPH oxidase/MAPKs/AP-1 and p300 in human tracheal smooth muscle cells |
| Q30402152 | Comparative modeling: the state of the art and protein drug target structure prediction |
| Q30393891 | Comprehensive Structural and Functional Characterization of the Human Kinome by Protein Structure Modeling and Ligand Virtual Screening |
| Q37697884 | Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. |
| Q39200193 | Cytokine profiles, signalling pathways and effects of fluticasone propionate in respiratory syncytial virus-infected human foetal lung fibroblasts |
| Q48946969 | Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD). |
| Q91645802 | Differential expression of heat shock proteins and activation of mitogen-activated protein kinases in A549 alveolar epithelial cells exposed to cigarette smoke extract |
| Q40026969 | Differential regulation of Moraxella catarrhalis-induced interleukin-8 response by protein kinase C isoforms. |
| Q27721394 | Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD) |
| Q53439673 | Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. |
| Q43258675 | Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma |
| Q42964153 | Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells |
| Q40147666 | Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling |
| Q38033010 | Epigenetics in asthma and COPD. |
| Q37852398 | Epigenetics of asthma |
| Q37006440 | Equine recurrent airway obstruction and insect bite hypersensitivity: understanding the diseases and uncovering possible new therapeutic approaches |
| Q33284018 | Evaluation of the utility of homology models in high throughput docking |
| Q35099151 | GSTM1 modulation of IL-8 expression in human bronchial epithelial cells exposed to ozone |
| Q83897571 | Gene expression profiling distinguishes radiation-induced fibrosing alveolitis from alveolitis in mice |
| Q28761895 | Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease |
| Q36346434 | Glutathione-S-transferase M1 regulation of diesel exhaust particle-induced pro-inflammatory mediator expression in normal human bronchial epithelial cells |
| Q45931397 | Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. |
| Q58877117 | Increased activation of p38 MAPK in COPD |
| Q46448195 | Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture |
| Q35903480 | Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids |
| Q43290696 | Interference of alpha-alkyl-substituted pirinixic acid derivatives with neutrophil functions and signalling pathways |
| Q35757161 | Intrapulmonary delivery of ricin at high dosage triggers a systemic inflammatory response and glomerular damage |
| Q38817765 | Inundation of asthma target research: Untangling asthma riddles |
| Q38882099 | Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. |
| Q47403914 | Lack of TAK1 in dendritic cells inhibits the contact hypersensitivity response induced by trichloroethylene in local lymph node assay |
| Q33766033 | Lead Screening for Chronic Obstructive Pulmonary Disease of IKK2 Inhibited by Traditional Chinese Medicine |
| Q23918409 | Lipopolysaccharide increases Na+, K+ -pump, but not ENaC, expression in guinea-pig airway epithelium |
| Q83398595 | Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro |
| Q37800575 | Mechanisms involved in lung cancer development in COPD. |
| Q34331434 | Mechanistic links between COPD and lung cancer |
| Q37235828 | Molecular mechanisms of corticosteroid resistance. |
| Q51962478 | Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. |
| Q47873103 | New approaches for identifying and testing potential new anti-asthma agents. |
| Q80810673 | New drugs for asthma |
| Q36485165 | New drugs targeting Th2 lymphocytes in asthma |
| Q37274728 | New targets for drug development in asthma |
| Q37765700 | New therapies for asthma: is there any progress? |
| Q37532557 | New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy |
| Q33753476 | Nicotine enhances murine airway contractile responses to kinin receptor agonists via activation of JNK- and PDE4-related intracellular pathways. |
| Q61712067 | Novel Anti-Inflammatory Treatments for Asthma and COPD |
| Q40041782 | Novel anti-inflammatory treatments for asthma |
| Q45991780 | Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. |
| Q37650688 | Opposing forces in asthma: regulation of signaling pathways by kinases and phosphatases |
| Q37756117 | Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches. |
| Q34159886 | Overlap Between Asthma and COPD: Where the Two Diseases Converge |
| Q42726097 | Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity |
| Q33873144 | Pathways analysis of molecular markers in chronic sinusitis with polyps |
| Q39333160 | Porphyrins as new endogenous anti-inflammatory agents |
| Q64008481 | Post-transcriptional regulators in inflammation: exploring new avenues in biological therapeutics |
| Q39968952 | Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH2-terminal kinase signaling |
| Q37685168 | Regulation of allergy with RNA interference |
| Q35029064 | Relationships between Cytokine Profiles and Signaling Pathways (IκB Kinase and p38 MAPK) in Parainfluenza Virus-Infected Lung Fibroblasts |
| Q83617314 | Relevance of systems pharmacology in drug discovery |
| Q39035070 | Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells. |
| Q37971131 | Severe asthma: advances in current management and future therapy |
| Q80140994 | Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form |
| Q37140072 | Steroid resistance in asthma: mechanisms and treatment options |
| Q39370971 | Synergism between interleukin (IL)-17 and Toll-like receptor 2 and 4 signals to induce IL-8 expression in cystic fibrosis airway epithelial cells. |
| Q37132582 | Targeting airway inflammation in asthma: current and future therapies |
| Q37955927 | Targeting airway smooth muscle in airways diseases: an old concept with new twists |
| Q38026246 | Targeting of TAK1 in inflammatory disorders and cancer |
| Q34493771 | The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma |
| Q34868949 | The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid |
| Q51661762 | The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients. |
| Q37010493 | The mast cell and allergic diseases: role in pathogenesis and implications for therapy |
| Q37966849 | The potential use of tyrosine kinase inhibitors in severe asthma |
| Q43237599 | The role of protein tyrosine phosphatases in the regulation of allergic asthma: implication of TC-PTP and PTP-1B in the modulation of disease development |
| Q38108873 | The therapeutic properties of Carapa guianensis. |
| Q37362620 | Therapeutic perspectives in bronchial vascular remodeling in COPD. |
| Q34571618 | Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. |
| Q61712269 | Transcription Factors |
| Q37329286 | Transcriptional regulation of cytokine function in airway smooth muscle cells. |
| Q37082594 | Treating COPD with PDE 4 inhibitors. |
| Q27011823 | Treatment of allergic asthma: modulation of Th2 cells and their responses |
| Q40588737 | Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage |
| Q37061880 | Viral infection in asthma |
| Q37988188 | p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD. |
| Q37886386 | p38 mitogen-activated protein kinase pathways in asthma and COPD. |
Search more.